Please login to the form below

Not currently logged in
Email:
Password:

US orders 1.4 million more doses of Regeneron antibody cocktail

The new $2.9bn order increases the amount of Regeneron’s anti-COVID REGEN-COV purchased by the US government to nearly 3 million doses

Two US government departments – Health and Human Services (HHS) and Defense (DoD) – will purchase an additional 1.4 million doses of Regeneron’s REGEN-COV (casirivimab and imdevimab) amid surging demand for the antibody cocktail.

REGEN-COV has been authorised for emergency use in the US for both treatment and prevention of COVID in patients deemed at high risk of progressing to severe disease.

“More than a year and a half into this pandemic, too many people are still being hospitalised and dying due to COVID-19," said Regeneron president and CEO, Leonard S Schleifer. "While vaccination remains the first line of defence to decrease the burden of COVID-19, REGEN-COV is a key tool that reduces the risk of hospitalisation or death by 70% in high-risk individuals when given early in the course of the infection.”

Regeneron will start to ship the extra doses immediately with the vast majority will be delivered in Q4.

REGEN-COV has not been approved by the Food and Drug Administration but was made available in November 2020 under emergency use approval for the treatment of COVID-19. The cocktail is not suitable for patients that already have severe COVID-19 but can be given to adults and children 12 or over with mild to moderate disease who are at high risk for progression to severe COVID-19, including hospitalisation or death.

In August, the emergency use was extended to cover post-exposure prophylaxis in adult and children 12 or over of COVID-19 who are at high risk for progression to severe COVID-19, including hospitalisation or death, and who have been in close contact with someone with the disease.

Under the new deal, the US government will pay $2,100 for each 1,200 mg dose of REGEN-COV, although patients receive the antibody combo free of charge.

Regeneron has also reported positive results from its phase 3 trials covering “the spectrum of COVID-19 infection, from prevention to hospitalisation”. This includes prevention of symptomatic infection in asymptomatic household contacts, treatment of non-hospitalised patients already infected with SARS-CoV-2, and treatment of certain patients hospitalised due to COVID-19 infection, including the UK RECOVERY trial.

Regeneron is collaborating with Roche to increase global supply of REGEN-COV, with Roche primarily responsible for development and distribution outside the US, although the Basel-based company will manufacture approximately one third of the newly ordered US doses.

Article by
Hugh Gosling

16th September 2021

From: Sales, Marketing

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...